Ankylosing Spondylitis and Other Seronegative Arthritis

Zacharia, Balaji; Roy, Anthony

doi:10.5772/intechopen.82332

Cited by 2 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Longer-term studies are also needed to determine whether these medicines are true disease modifiers in AS. In this chapter, we will discuss in-depth the treatment modalities currently employed and understudied for the treatment of AS [2,4,9].…”

Section: Introductionmentioning

confidence: 99%

Treatment Modalities of Ankylosing Spondylitis

Srivastava¹,

Pant²,

Srivastava³

et al. 2023

Ankylosing Spondylitis - Recent Concepts

View full text Add to dashboard Cite

Ankylosing spondylitis is a chronic inflammatory arthropathy of young adults which primarily affects the axial skeleton. The pathogenesis of AS is unclear, but it is thought to be caused by an early inflammatory phase followed by ossification that may induce local osteitis. It has also been linked to an increase in morbidity and mortality and is known to have a debilitating impact on QoL of the patients. Whereby, CRP and ESR are used for assessment of the disease activity and determination of treatment efficacy, HLA-B27 is considered the best biomarker for AS diagnosis. The conventional therapeutic regimen like NSAIDs and DMARDs alone are not effective in controlling symptoms and indicators of disease; however, when combined with the physical therapy, great improvement in the QoL of the patients has been observed. The outlook for AS has improved remarkably with the advent of biologics that blocks key inflammatory cytokines such as TNF inhibitors. Biologics aids in halting disease progression, and can be used concomitantly with other medications for pain management. In this chapter, barring surgical interventions, we will discuss about the non-pharmacological and pharmacological therapies routinely employed for the treatment of AS, as well as the novel therapeutics currently under study.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment Modalities of Ankylosing Spondylitis

Srivastava¹,

Pant²,

Srivastava³

et al. 2023

Ankylosing Spondylitis - Recent Concepts

View full text Add to dashboard Cite

show abstract

“…At the end of the 20th century -the beginning of the 21st century, the results of several scientific studies conducted in Europe and North America proved that Chlamydia trachomatis is a trigger agent of reactive arthritis (ReA), seronegative spondyloarthritis (SpA) with a possible important role in undifferentiated seronegative oligoarthritis, undifferentiated monoarthritis syndrome and rheumatoid arthritis (RA) [2,4,9]. To date, clinical manifestations, changes in laboratory data and the results of instrumental examinations of joints and spine in axial seronegative spondyloar-…”

Section: Introductionmentioning

confidence: 99%

“…La sfârșitul secolului XX -începutul secolului XXI, rezultatele mai multor studii științifice efectuate în Europa și America de Nord au demonstrat că Chlamydia trachomatis este un agent trigger al artritei reactive (ReA), spondiloartritelor seronegative (SpA) cu posibil rol important în oligoartrita seronegativă nediferențiată, sindromului de monoartrită nediferențiată și a artritei reumatoide (RA) [2,4,9]. Până în prezent, nu au fost elucidate pe deplin manifestările clinice, modificările parametrilor de laborator și rezultatele examinărilor instrumentale ale articulațiilor și coloanei vertebrale în spondiloartritele seronegative axiale (aSpA) cu rol trigger de Chlamydia trachomatis.…”

Section: Introducereunclassified

Trigger impact of Chlamydia trachomatis on various types of seronegative spondyloarthritis

Chișlari¹,

Groppa²,

Russu³

et al. 2022

MJHS

View full text Add to dashboard Cite

Introduction. To date, clinical manifestations, laboratory changes and the results of instrumental examinations of the joints and spine in axial seronegative spondyloarthritis (aSpA) caused by Chlamydia trachomatis have not been fully elucidated. Purpose of the study: evaluation of clinical manifestations features, diagnosis, and evolution of seronegative spondyloarthritis associated with Chlamydia trachomatis infection. Objectives of the study: To compare clinical manifestations, changes in laboratory parameters, results of instrumental examinations of the joints and spine in seronegative spondyloarthritis, the axial, peripheral, and mixed form. To appreciate the significance of Chlamydia trachomatis in the development of SpA by detecting the presence of DNA using the polymerase chain reaction (PCR) in real time and by isothermal amplification of NASBA-PCR (Nucleic acid sequence-based amplification). Material and methods. During 2015-2021 were examined 138 patients with SpA hospitalized in the Republican Clinical Hospital „Timofei Moşneaga”. Chlamydia trachomatis in the form of monoinfection was detected in 87 (6.3%) patients, of which 52 (59.8%) were women and 35 (40.2%) men. Results. The results of the diagnosis of Chlamydia trachomatis infection in patients with arthritis: Chlamydia trachomatis infection was detected in 78 (89.7%) out of 87 patients examined by PCR, and in 9 (10.3%) cases by ELISA. The peripheral form begins mainly with inflammation of the joints of the lower extremities (81.8%), of which the knee joints are mainly involved in the pathological process (63.6%). SpA axial form associated with Chlamydia trachomatis infection occurs mainly in young men (85.7%). In more than half of the patients, large joints participate in the pathological process (58.8%), especially the lower extremities. The axial variant of the SpA can begin with an injury in any part of the spine. Discussions. SpA associated with Chlamydia trachomatis infection has more expressed clinical, laboratory and instrumental manifestations both in the onset and in the advanced stage of the disease.

show abstract

Ankylosing Spondylitis and Other Seronegative Arthritis

Cited by 2 publications

References 35 publications

Treatment Modalities of Ankylosing Spondylitis

Treatment Modalities of Ankylosing Spondylitis

Trigger impact of Chlamydia trachomatis on various types of seronegative spondyloarthritis

Contact Info

Product

Resources

About